Publication | Open Access
CYP 2D6 polymorphism: A predictor of susceptibility and response to chemoradiotherapy in head and neck cancer
23
Citations
0
References
2012
Year
Cancer therapy outcomes are unpredictable, largely due to pharmacogenetic variability in drug‑metabolizing enzymes, prompting a case‑control study of 100 male head‑and‑neck squamous cell carcinoma patients and matched healthy controls. The study genotyped CYP2D6 polymorphisms by extracting genomic DNA from blood of patients and controls and applying PCR‑RFLP analysis. Carriers of CYP2D6*4 or *10 variants showed a significantly increased risk of head‑and‑neck squamous cell carcinoma and poorer response to cisplatin‑based chemoradiotherapy, with smoking, tobacco, and alcohol use further amplifying these effects, underscoring the role of CYP2D6 polymorphisms in disease susceptibility and treatment outcomes.
A major problem in cancer pharmacology is the unpredictability of the outcome of therapy, both in terms of tumor response and host toxicity. Pharmacogenetic variability associated with the drug metabolizing enzyme systems is a major determinant of variations in these outcomes.A case-control study of 100 male cases of head and neck squamous cell carcinoma and equal number of healthy controls was conducted. Genomic DNA isolated from blood samples collected from controls and patients was studied by PCR-RFLP technique for CYP2D6 polymorphism. All patients received three cycles of cisplatinum-based sequential chemoradiotherapy.The increased frequency of variant genotypes was associated with a statistically significant increase in the risk in the cases both in CYP2D6*4 and *10. The effect of interaction of the risk modifiers such as cigarette smoking or tobacco chewing or alcohol drinking with the CYP2D6 genotypes in the controls and patients was found to be significant. Response to therapy in patients with variant genotypes of CYP2D6 (CYP2D6*4 and CYP2D6*10) and treated with radio and chemotherapy regimen was poor.Functional enzyme deficiencies due to polymorphism in CYPs are not only important in enhancing susceptibility to head and neck squamous cell carcinoma but also in determining chemotherapeutic response.